Obesity drug race heats up as Innovent uncorks new GLP1 data
While Eli Lilly has been hyper-focused on dethroning Novo Nordisk’s semaglutide in the diabetes and obesity space, another challenger sneaked up from behind.
Innovent Biologics burst onto the scene Tuesday with Phase II data showing its GLP-1 receptor/glucagon receptor dual agonist reduced patients’ body weights by more than 12% at the highest dose compared to placebo.
The obesity study enrolled 248 Chinese participants with 230 completing a full 24 weeks of treatment on either varying doses of once-weekly mazdutide injections or placebo. At the highest 6-mg dose, mazdutide patients saw an 11.57% reduction in body weight from baseline, compared to the 1.05% reduction seen by placebo patients (p < 0.0001). That compares to a 7.21% reduction from baseline on the lowest dose, 3 mg.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.